![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 13 of 13. This is the beginning of the thread.
Posted by jrbecker on September 10, 2004, at 10:29:02
The list has been updated to also include antipsychotics....
Posted by SLS on September 10, 2004, at 11:10:03
In reply to List of Drugs in Development [updated], posted by jrbecker on September 10, 2004, at 10:29:02
> The list has been updated to also include antipsychotics....
>
>
> http://www.neurotransmitter.net/newdrugs.html
Will "Thank you" do it for you?
- Scott
Posted by Jaynee on September 10, 2004, at 21:43:00
In reply to List of Drugs in Development [updated], posted by jrbecker on September 10, 2004, at 10:29:02
Posted by sb417 on September 10, 2004, at 23:11:29
In reply to List of Drugs in Development [updated], posted by jrbecker on September 10, 2004, at 10:29:02
You guys are the best! Thank you!
Posted by incessant void on September 11, 2004, at 21:26:13
In reply to List of Drugs in Development [updated], posted by jrbecker on September 10, 2004, at 10:29:02
that's a great chart, thank you so much!
i'm interested in "DOV216,303" -- clicked on the link you had and the site said:
" recently completed a dose-escalating, placebo-controlled, double-blind Phase I clinical trial in France that evaluated the blood levels and side effect profile produced by single doses of DOV 216,303. DOV 216,303 was rapidly absorbed following oral administration, with blood levels proportional to the administered dose. No adverse effects were observed after doses five to ten times higher than the projected therapeutic doses. We initiated a Phase Ib multiple dose-ranging clinical trial of DOV 216,303 in April 2002."
do you have any more info? shouldn't this drug be further along than stage II? :(
Posted by poop'd-out on September 12, 2004, at 2:18:46
In reply to List of Drugs in Development [updated], posted by jrbecker on September 10, 2004, at 10:29:02
Posted by jrbecker on September 13, 2004, at 15:34:15
In reply to Re: List of Drugs in Development [updated], posted by incessant void on September 11, 2004, at 21:26:13
DOV just signed a big deal with Merck on the triple reuptake molecules. It's my guess that Merck is deciding which molecule (DOV 216,303 in Phase IIb; or DOV 21,947, starting up Phase II) to proceed with.
I believe that DOV was going to make some sort of announcement about one of DOV216,303's phase II results in 4Q. But we won't know for at least a few months if Merck will continue into phase III with 216,303 or will wait to see more trials on 21,947 first.
http://biz.yahoo.com/prnews/040805/nyth135_1.html
http://www.dovpharm.com/sub_page/product_dov216303.html
you will need the free microsoft powerpoint viewer software to see these slides...see "2nd Annual Science Day Presentations"
http://www.b2i.us/Profiles/Investor/Presentation.asp?BzID=590&sm_quote_field=DOVP&CName=DOV+Pharmaceutical%2C+Inc%2E
> that's a great chart, thank you so much!
>
> i'm interested in "DOV216,303" -- clicked on the link you had and the site said:
>
> " recently completed a dose-escalating, placebo-controlled, double-blind Phase I clinical trial in France that evaluated the blood levels and side effect profile produced by single doses of DOV 216,303. DOV 216,303 was rapidly absorbed following oral administration, with blood levels proportional to the administered dose. No adverse effects were observed after doses five to ten times higher than the projected therapeutic doses. We initiated a Phase Ib multiple dose-ranging clinical trial of DOV 216,303 in April 2002."
>
> do you have any more info? shouldn't this drug be further along than stage II? :(
>
Posted by jack smith on September 15, 2004, at 1:28:24
In reply to List of Drugs in Development [updated], posted by jrbecker on September 10, 2004, at 10:29:02
Wasn't there a substance P/nk1 antagonist in phase III trials last year for depression -- I thought it was the one that had been approved for chemotherapy. What happened to that?
Inquiring minds want to know,
JACK
> The list has been updated to also include antipsychotics....
>
>
> http://www.neurotransmitter.net/newdrugs.html
Posted by SLS on September 15, 2004, at 5:05:32
In reply to Substance P » jrbecker, posted by jack smith on September 15, 2004, at 1:28:24
> Wasn't there a substance P/nk1 antagonist in phase III trials last year for depression -- I thought it was the one that had been approved for chemotherapy. What happened to that?
Hi Jack.Aprepitant (Emend) has been FDA approved. I think this is the drug you are talking about.
- Scott
Posted by jack smith on September 16, 2004, at 1:24:57
In reply to Re: Substance P, posted by SLS on September 15, 2004, at 5:05:32
> Hi Jack.
>
> Aprepitant (Emend) has been FDA approved. I think this is the drug you are talking about.
>
>
> - Scott
>Hey Scott,
Sure that's the one, but I thought it was in clinical trials for depression specifically. Has it been approved for that? As far as I know the pricing on it for chemo is very high, such that it could not be used in significant off-label amounts to treat depression. Do you or jr know if it is still being tested for depression?
JACK
Posted by jack smith on September 16, 2004, at 1:29:32
In reply to Re: Substance P, posted by SLS on September 15, 2004, at 5:05:32
> Hi Jack.
>
> Aprepitant (Emend) has been FDA approved. I think this is the drug you are talking about.
>
>
> - Scott
>Ask Google and ye shall receive,
I guess there's our answer:
Another one bites the dust. So much promise for this substance P thing, oh well, guess it was just a bunch of BS hype.
Posted by jrbecker on September 16, 2004, at 9:46:34
In reply to OUCH, posted by jack smith on September 16, 2004, at 1:29:32
> > Hi Jack.
> >
> > Aprepitant (Emend) has been FDA approved. I think this is the drug you are talking about.
> >
> >
> > - Scott
> >
>
> Ask Google and ye shall receive,
>
> I guess there's our answer:
>
> http://www.ingenta.com/isis/searching/Expand/ingenta?pub=infobike://adis/inp/2003/00000001/00001414/art00022
>
> Another one bites the dust. So much promise for this substance P thing, oh well, guess it was just a bunch of BS hype.
Drug trials are a lot more complicated than that. The methodology involved is an extremely intricate process. We shouldn't discount a drug class's potential based on one failed trial.Numerous drug companies are involved with mid-phase testing of their own NK1, NK2 and NK3 compounds. And it's most likely that some of them will find their way to market.
On a totally unrelated subject...after all of your apprehensive awaiting of Cymbalta, have you decided to take it yet?
Posted by jack smith on September 16, 2004, at 18:49:24
In reply to Re: OUCH » jack smith, posted by jrbecker on September 16, 2004, at 9:46:34
> On a totally unrelated subject...after all of your apprehensive awaiting of Cymbalta, have you decided to take it yet?
>Tempted, but since Effexor is working pretty well for me, I don't want to rock the boat. I guess if, god forbid, Effexor ever poops out, I'll try it. Just can't stand the sexual side effects from Effexor, but I am thinking that Cymbalta will not be much better in that department. I'll see how it works for others.
JACK
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.